key: cord-0833726-yo6jf3ng authors: Deng, Jia-gang; Hou, Xiao-tao; Zhang, Tie-jun; Bai, Gang; Hao, Er-wei; Chu, Justin Jang Hann; Wattanathorn, Jintanaporn; Sirisa-ard, Panee; Soo Ee, Ch'ng; Low, John; Liu, Chang-xiao title: Carry forward advantages of traditional medicines in prevention and control of outbreak of COVID-19 pandemic date: 2020-06-02 journal: Chin Herb Med DOI: 10.1016/j.chmed.2020.05.003 sha: ff6b044130a4dd3c9838e9faa71f10607cebd5d5 doc_id: 833726 cord_uid: yo6jf3ng Members of the China-ASEAN Joint Laboratory for International Cooperation in Traditional Medicine Research used the video conference platform to exchange and discuss the advantages of traditional medicine through the form of score exchange and report, and research and develop the amount and issues of the therapeutic COVID-19 products of concern. This paper manly reviews the achievements of the implementation of the epidemic prevention and control plan, advances of scientific basic studies on SARS-CoV-2, analysis and screening of potential targets and pathways of antiviral compounds based on network pharmacology and development of antiviral food dual-use products. The authors believe that the declaration of the (10+3) special meeting of national leaders on epidemic prevention and control should raise the medical and pharmaceutical issues of common concern. It is the responsibility of our joint laboratory members to accelerate the development of traditional medicine research and industry. Also the authors believe that this exchange will certainly promote the development of the cause of cooperation. The world is facing unprecedented health threats, social and economic shocks from COVID-19. World Health Organization (WHO) is to address the global impact of the COVID-19 pandemic. WHO reported that the world has now been more than 3.5 million cases of COVID-19 (WHO, 2020) . Around the world, the pandemic has caused severe disruption to essential health services, including to community-based health care, and in many countries trained members of the community play a vital role in delivering essential health services like vaccination, drug screening, clinical detection, prevention and management of the diseases. We must address this now and in the long-term by prioritizing diagnosis and care for those who are most at risk. The WHO will help communities most at risk by scaling up local medical and public health efforts and better protect people around the world from future pandemics. At this grim time, the timely convening of the Asia-Pacific (10+3) special video-meeting demonstrates the responsibility of countries in the Asia-Pacific region. The statement and declaration of the special session pointed the way to how our co-laboratory could exploit the advantages of traditional medicines. The commitment to strengthen solidarity, enhance cooperation and mutual support among the APT countries to control and contain the spread of the pandemic, addressing the adverse impact of the pandemic on our societies and economies. The ASEAN countries hereby resolve to 18 terms. The Strengthen 5 points out that "scientific cooperation in epidemiological research, including through the APT Field Epidemiology Training Network, coordination, including with the private sector, towards rapid, research, development, manufacturing and distribution of diagnostics anti-viral medicines and vaccines, adhering to the objectives of efficiency, safety, equity accessibility and affordability", and the Strengthen 15 points out that "efforts to stabilize the manufacturing and supply of essential goods and services, including vital medical supplies, critical agricultural products, maintain necessary flow of goods and services and sustain supply …… in order to support economic development, reaffirming our commitment described in the Joint Leader's Statement on the Regional Comprehensive Economic Partnership released in 2019" (China Daily, 2020) . We learned from the conference documents that the two articles had great responsibilities for experts in joint laboratories engaged in the research, development and application of traditional medicines. We are also holding a joint laboratory work meeting on this important day (5 th May) to share research advances and innovations in the fight against the epidemic using traditional drug services in the Asia-Pacific region. During the epidemic, we also carried out some theoretical and applied studies and published several papers (Liu 2020a; Liu 2020b; Liu, wang & Yan, 2020; Liu wang & Zang et al., 2020a; Liu, wang & Zang et al.,2020b; Liu, Yi & Wang et al., 2020; Han et al., 2020; Qin et al., 2020) . This article will focus on the expert discussion and reports contents. Nankai University was involved in the development of diagnostic reagents and techniques to combat with COVID-19, and developed COVID-19 IgM/IgG antibody detection kit. By integrating AI technology and CT images, the new diagnostic technique was successfully used in clinical detection of COVID-19. In order to rapidly discover lead compounds for clinical use, researchers identified a mechanism-based inhibitor, N3, by computer-aided drug design and subsequently determined the crystal structure of COVID-19 virus Mpro (3CLpro) in complex with this compound. An initiated program of combined structure-assisted is used for drug design, virtual drug screening and high-throughput screening to identify new drug leads that target the COVID-19 virus main protease was designed (Jin et al., 2020) . The RNA-dependent RNA polymerase (RdRp, also named nsp12) is the central component of coronaviral replication/transcription machinery and appears. Researchers also report the cryo-EM structure of COVID-19 virus full-length nsp12 in complex with cofactors nsp7 and nsp8 at 2.9-Å resolution. A comparative analysis model shows how Remdesivir binds to this polymerase. The structure provides a basis for the design of new antiviral therapeutics targeting viral RdRp (Gao et al. 2020) . By actively carrying out joint research, the structure of COVID-19 key proteases, 3CLpro and RdRp have been published in Science and Nature. A series of lead compounds were screened for COVID-19 related targets from natural product compound library. Mangiferin is well-known xanthone in mango fruits, barks, peel, leaves and stone. The compound has potential pharmacological effects, such as antioxidant, antiaging, antiviral, hepatoprotective, analgesic and immunomodulatory activities (Imran et al. 2017) . Mangiferin is a natural miracle bioactive compound against lifestyle related disorders. Baicalin is derived compound from the plant Scutellaria baicalensis Georgi. It is famous in many countries, including the Russian Federation, European countries and several East Asian countries, for its potential pharmacological properties including anti-inflammation effect, apoptosis modulation, autophagy induction, cell cycle arrest, metastasis suppression and oxidative stress inhibition and so on (Li et al, 2019) . From the pharmacological actions of them, we suggested that the two compounds maybe have relation with antivirus of SARS-CoV-2. Prof. Bai's team at Nankai University in China used the PyMOL software to display the 3D map of the interaction of mangiferin with Mpro (PDB: 6LU7). The interactions between the mangiferin and the protein include hydrogen bond interactions with LEU141, SER-144, ). The software was also used to display the 3D map of the interaction of baicalin ( Chinese Academy of Engineering (CAE) to protest the development of a major project "Lanzhi Bacteriostatic Solution" (Research and development of new Chinese medicine sprayers based on COVID-19 TCM prevention and control strategies) has been approved by Academician Chang-xiao Liu and the Chinese medicine team of Tianjin Institute of Pharmaceutical Research (TJIPR). Based on the epidemic characteristics and prevention and control countermeasures and traditional Chinese medicine for external use in fire prevention theory and experience, design suppresses environmental pathogenic microorganisms and human conditioning qi activity for the principle formula, in raw materials, logistics, testing, processing is very difficult to special circumstances, complete Chinese medicine epidemic prevention and control product "Lanzhi Antibacterial Liquid (spray type)", complete the production of 20000 bottles of products, and giving the epidemic area. After the outbreak of COVID-19, the research team of GXUCM responded actively, and the application for two special science and technology projects to prevent and control pneumonia caused by SARS-CoV-2 in Guangxi in 2020 was approved, including Sino-Singapore cooperation for evaluating the effectiveness and application of Guangxi Zhuang/Yao medicines against undertook sub-topics. This formula can be used to treat the deficiency of spleen and lung, deficiency of qi and yin, shortness of breath, tiredness, tolerance and vomiting, or low heat, dry cough with less phlegm, dry mouth, thirst, palpitations, excessive sweat, insufficient sleep, weak stool and irritated stools during the recovery period after discharge. Tongue light fat or dry tongue less fluid, moss white greasy or less moss, veins fine or weak and so on. It can also be used as a source of qi-yin deficiency or yin deficiency holding wet constitution people daily conditioning drinking. The early symptoms SARS-CoV-2 infection was fever, dry cough, sore throat, fatigue, etc. At the beginning, patients were mainly with the plague rage infringement throat, causing acute inflammation. At present, the oral preparations are the preferential therapy. The Guangxi project team developed a contain gargle solution "antipyretic wet nurse liquid", for the epidemic prevention and control. Using six kinds of traditional Chinese and ethnic medicines including Atractylodis Rhizoma (Artemisia annua L. and Aractylodes lancea (Thunb.) DC.) etc., in Chinese medicine and national medicine formula. The preparation is given locally in the mouth, which can increase the contact surface between the drug and the lesion, enhance the efficacy of clearing heat, changing humidity, and improving pharyngeal protection. Currently, the product prescription and process research have been completed, and the simple archival materials of traditional Chinese medicine and ethnic medicine preparations have been submitted to the food and drug administration of Guangxi Zhuang Autonomous Region, China. The National University of Singapore has established the state of the art BSL3-Core facility in the Yong Loo Lin School of Medicine as a screening technology platform for drug discovery research against SARS-CoV-2. The BSL-3 Core Facility, led by Associate Professor Justin Chu, has successfully isolated and cultured the SARS-CoV2 from COVID-19 patients from the hospitals .In view of the coronavirus replication cycle, 54 chemical components in the library of GXUCM and 461 chemical components in the library of ACE2 receptor inhibitors are being screened for anti-SARS-CoV-2 virus activity. After screening the active compounds, a human ACE2 transgenic mouse model will be established to study the anti-SARS-CoV-2 virus activity in vivo. With this platform, target prediction was carried out to achieve high-throughput screening (Fig. 3) and screening scheme design (Fig. 4) to obtain valuable information. The project team searched the domestic and foreign literatures, screened the reported compounds with anti-coronavirus, influenza virus and HIV, and prepared 54 active chemical components through purchase and isolation. The team studied the chemical composition analysis of potential targets and pathways of 54 potential antiviral preparations, and screened and found the total of 87 potential targets in the database. They also obtained information on the protein and the protein interaction network, download protein-protein interaction information using Cytoscape software, according to the network topology parameters selected is greater than 2 times the average degree of targets, the targets play a pivotal role in the network, key targets for received 49. The network topological parameters of compounds and targets were visualized by Cytoscape software. The results showed that the top five compounds were resveratrol, genistein, estradiol, berberine and baicalein. The top five targets were TP53, AKT1, BCL2, NOS3 and CDKN1A. They also detected the neutralization activity of the pseudovirus, and initially found four compounds with potential antiviral activity, and one compound extract of traditional Chinese medicine. Currently, a cell based assay is being used for activity validation in the NUS Medicine Biosafety Level 3 Research Facility, a research unit in the National University of Singapore. During January 20, 2020 to March 23, 2020, the project team has collected 25 guiding documents, such as the latest version of diagnosis and treatment plans, prevention and treatment plan, and technical guidelines, which have been published by the National Health Commission and the health commissions of 24 provinces, autonomous regions and municipalities directly under the central government. Collection of treatment prescription information in each program, the establishment of a database, including prescription name, drug name, efficacy classification, sexual taste, efficacy indications, treatment, disease stage and other information. Using EXCEL, Graphpad 8.0, SPSS Modeler18.0 and other software, the paper made a statistical analysis on the usage frequency, classification frequency, properties and compatibility characteristics of all kinds of traditional Chinese medicines. A total of 137 prescriptions of traditional Chinese medicine for treating COVID-19 were collected, and 178 herbs were included. Chinese medicine with the functions of clearing heat, tonifying deficiency, resolving phlegm, relieving cough and asthma, relieving exterior syndrome, resolving dampness, clearing damp and promoting diuresis were the mainly used Chinese medicine, in which types of resolving phlegm, relieving cough and asthma, resolving dampness, clearing damp and promoting diuresis accounted for 35.78%. There were also a considerable number of medicines with the function of removing dampness in the types of clearing heat, tonifying deficiency and relieving exterior syndrome. It can be seen that the medicines with the function of removing dampness was the first choice in the treatment of COVID-19 with Chinese medicine. The Chinese medicine with the function of aromatic resolving dampness, clearing heat and drying dampness, drying dampness and tonifying spleen qi, drying dampness and removing phlegm, promoting diuresis and relieving swelling, promoting diuresis and relieving exterior syndrome were mainly used Chinese medicine for removing dampness. Among them, the most frequently used medicine was Tianjin Institute of Pharmaceutical Research carried out the development of special medical food. According to the needs of covid-19 nutrition support, the institute seizes the time to develop new special medical food "Yiyiyuan" during the epidemic and has completed the production of 20,000 boxes of finished products that was donated to Hubei epidemic areas, China. Dr. Panee Sirisa-ard, associate professor, University of Chiangmai, Thailand, studied a kind of medicinal mushroom that can improve the immunity of patients. It has the application of resistance to H1N1 virus. At present, the mechanism of action of this mushroom has been studied. It is looking forward to funding the research. Keding International Co., Ltd. Aponte, which is mainly made of Ganoderma lucidum in tiger milk, has a good effect on pulmonary infection. are almost cheap kitchen "medicine" one of the world's most countries, especially Southeast Asian countries like to eat. They contain antibacterial and antiviral compounds, anti-inflammatory, antioxidant, anti-tumor effects, but also conducive to the human body to improve immunity, to fight against "pathogen invasion". Garlic and onions contain 70 phytochemicals that reduce the risk of hypertension. Ginger has a warm and spicy taste, which can enhance blood circulation, stimulate gastric juice secretion, stimulate the intestines and promote digestion. It can play sweating, cooling, and relieve fatigue, fatigue, anorexia, insomnia, abdominal distension, abdominal pain, and so on. The antioxidant, anti-inflammatory and immune-modulation effects are beneficial in improving initial symptoms for COVID-19 patients. The prevention and control of the COVID-19 epidemic is a top priority for the world. WHO recognizes that traditional, complementary and alternative medicine has many benefits in public health care. We know that the traditional herbal products are very value for treatment and prevention of COVID-19, but note that it needs to research and select traditional medicine products in clinical efficacy and safety for COVID-19 treatment. WHO welcomes every opportunity to collaborate with countries and researchers to develop new therapies and encourages such collaboration for the development of effective and safe therapies. It concerns not only the safety of the people, but also the stability and development of the world. The members of the China-ASEAN joint laboratory of traditional medicine use the video conference platform to exchange and discuss the advantages of traditional medicine through the form of score exchange and report, and research and develop COVID-19 product amount and issues of concern to research and development. In summary, this paper manly contents achievements of the implementation of the epidemic prevention and control plan, advance of scientific basic studies on SARS-CoV-2, analysis and screening of potential targets and pathways of antiviral compounds based on network pharmacology and development of antiviral food dual-use products. The authors believe that the declaration of the (10+3) special meeting of national leaders on epidemic prevention and control should raise the issue of medical and pharmaceutical issues of common concern. It is the responsibility of our joint laboratory members to accelerate the development of traditional medicine research and industry. Therefore, we believe that this exchange will certainly promote the development of the cause of cooperation in traditional medicines. The authors declare no conflict of interests. Joint Statement of the Special ASEAN plus Three (APT) Summit on Coronavirus Diseases-2019 (COVID 2019) Structure of the RNA-dependent RNA polymerase from COVID-19 virus Mechanism of Tanreqing Capsule on treatment of coronavirus disease 2019 based on network pharmacology Mangiferin: a natural miracle bioactive compound against lifestyle related disorders Structure of Mpro from COVID-19 virus and discovery of its inhibitors Baicalin mitigated Mycoplasma gallisepticum-induced structural damage and attenuated oxidative stress and apoptosis in chicken thymus through the Nrf2/HO-1 defence pathway Pay attention to situation of SARS-CoV-2 and TCM advantages in treatment of novel coronavirus infection Drug-therapy for novel coronavirus infection: compassionate use and its implications Understanding novel coronavirus pneumonia, paying attention to research and development of epidemic prevention and control drugs Using "compartment model" dynamics to understand the transmission regularity of coronavirus disease 2019 (COVID-19) during the outbreak period Attach importance to research and development of Chinese materia medica based on prevention and control needs of SARS-CoV-2 infection Understanding coronavirus (SARS-COV-2) and thinking about strategy of antiviral drug development. Drug Evaluation Research Screening active components of anti-SARS-CoV-2 from Yao medicine named "eighteen zuan" by literature mining and molecular docking technology WHO (2020) Director-General's opening remarks at the media briefing on COVID-19 -6 Authors thank for the support of the science foundation projects: (1) Chinese Academy of